Asia Press Agency

Tag: Glenmark Life Sciences

  • Glenmark Life Sciences Announces Interim Dividend

    Glenmark Life Sciences Announces Interim Dividend

    Glenmark Life Sciences, a prominent player in the pharmaceutical industry, has delighted its investors by announcing an interim dividend of ₹22.50 per equity share for the financial year 2023-24. This move demonstrates the company’s commitment to providing returns to its shareholders while continuing its operations and growth initiatives.

     

    The announcement comes following a board meeting held on October 9, 2023, where the decision to declare the interim dividend was made. The payment of this dividend is scheduled for October 23, 2023, and shareholders eligible for this payout will be determined based on their holdings as of the record date, which is set for October 17, 2023.

     

    Glenmark Sciences’ decision to declare this interim dividend reflects the company’s financial strength and stability. It is a gesture that acknowledges the trust and confidence that investors have placed in the company. Dividends are a way for companies to share their profits with shareholders and provide them with a tangible return on their investment.

     

    The pharmaceutical industry is known for its research-intensive and capital-intensive nature, and companies like Glenmark Sciences often make substantial investments in research and development to bring innovative medicines and healthcare solutions to market. Despite the challenges and uncertainties that can accompany the pharmaceutical business, Glenmark Life Sciences’ ability to declare a significant dividend reflects its strong financial position.

     

    In addition to this dividend declaration, Glenmark Life Sciences has been in the spotlight due to a strategic move made by its parent company, Glenmark Pharmaceuticals. Glenmark Pharmaceuticals recently announced the sale of a 75% stake in Glenmark Life Sciences to Nirma, a prominent conglomerate with interests in various sectors.

     

    This deal, valued at ₹5,651.5 crore, places an overall valuation of ₹7,535.4 crore on Glenmark Life Sciences. As part of the transaction, Nirma will initiate a mandatory open offer to acquire an additional 17.15% stake in Glenmark Life Sciences at ₹631 per share. It’s worth noting that Glenmark Life Sciences made its stock market debut in August 2021 at an IPO price of ₹720 per share.

     

    The funds generated from the sale of shares to Nirma will serve as a valuable resource for Glenmark Pharmaceuticals to repay its debt obligations. Even after the completion of this transaction, Glenmark Pharmaceuticals will retain a 7.84% stake in Glenmark Life Sciences, signaling its ongoing commitment to the company.

     

    Overall, Glenmark Life Sciences’ interim dividend declaration is a positive development that underscores its financial health and investor-friendly approach. It aligns with the company’s mission to deliver value not only through its pharmaceutical products and innovations but also through rewarding its shareholders for their support and investment in the company’s journey.

  • Glenmark Life Sciences Q1FY24 Performance: Robust Revenue

    Glenmark Life Sciences Q1FY24 Performance: Robust Revenue

    Glenmark Life Sciences Ltd posted a total revenue of ₹5,784.5 million for the quarter ending in June (Q1FY24), registering a substantial 18% year-on-year increase. The net profit during this period also showed a noteworthy growth, standing at ₹1,354.5 million, which is a 24% increase compared to the previous year.

     

    The active pharmaceutical ingredients (API) manufacturing arm of Glenmark Pharmaceuticals (GPL) witnessed a 14.1% YoY rise in the cost of raw materials, amounting to ₹2,982.13 million in the current fiscal year. The company’s EBITDA (earnings before interest, taxes, depreciation, and amortization) reported a significant growth of ₹1,950 million, a 24.8% rise YoY. During the quarter, Glenmark Life Sciences demonstrated robust free cash generation, amounting to ₹982 million, leading to cash & cash equivalents of ₹3,820 million as of June 30.

     

    Yasir Rawjee, managing director and chief executive of Glenmark Life Sciences, attributed the quarter’s strong performance to the success of the Generic API and the CDMO businesses. The company experienced growth across various geographic markets, including the US, Europe, Rest of the World (RoW), and India. Rawjee emphasized the company’s focus on strategic priorities, such as capacity building and strengthening the product pipeline. Along with an improved demand environment and supply situation, these efforts are expected to drive growth in the upcoming quarters.

     

    The contract development and manufacturing operations (CDMO) segment of the company, constituting 8% of its overall business, recorded a revenue of ₹464 million in Q1FY24, a remarkable 91% growth YoY.

     

    The Generic API revenues for Q1FY24 rose by 13.3% YoY to ₹5,042 million, primarily driven by strong growth in regulated markets of the US and Europe, along with a robust performance in the India market fueled by ex-GPL business. GPL business in Q1FY24 also increased by 18.6% YoY, amounting to ₹1,964 million, according to the company’s statement.

     

    Glenmark Life Sciences revealed its plans for expansion, indicating the completion of a 208KL intermediate block at the Ankleshwar site, contributing to a total manufacturing capacity of 400 KL, which is expected to be operational in the second half of FY24. Additionally, the company is adding a 50KL pharma capacity this year in Dahej, Gujarat.

     

    Glenmark Life Sciences specializes in the development and manufacturing of select, high-value, non-commoditized active pharmaceutical ingredients in chronic therapeutic areas. The company’s positive Q1FY24 results reflect its commitment to growth and expansion in the pharmaceutical industry.